secwatch.observer — SEC 8-K summary
======================================

Issuer:     LENZ Therapeutics, Inc. (LENZ)
CIK:        0001815776
Form:       8-K
Filed at:   2023-08-23T23:59:59+00:00
Accession:  0000950170-23-044135
Event type: other_material
Sentiment:  negative
Materiality: 0.85
Item codes: 8.01, 2.05, 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Graphite Bio appoints new CEO, cuts 70% of workforce
----------------------------------------------------

- Kimberlee C. Drapkin appointed President & CEO, effective Aug 21, 2023; base salary $550,000.
- Board approved a restructuring plan reducing workforce by approximately 70%.
- Estimated severance and related costs of ~$1.6 million, recorded primarily in Q3 2023.
- Former CEO Josh Lehrer separated; entitled to Tier 1 severance and retention benefits.
- Company continues exploring strategic alternatives as part of corporate restructuring.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1815776/000095017023044135/0000950170-23-044135-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1815776/000095017023044135/grph-20230818.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-044135

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer